Neogap Therapeutics receives EMA’s ATMP classification for its personalised cancer cell therapy

Neogap Therapeutics AB, a Swedish clinical-stage biotechnology company, announces that the European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product (ATMP) classification to its cell therapy, pTTL (personalised Tumour Trained Lymphocytes). This classification confirms that pTTL meets the regulatory criteria for a somatic cell therapy product, providing a clear regulatory pathway for its further development. [Neogap-Therapeutics-receives-EMA-ATMP-classification-for-personalised-cancer-cell-therapy.png] The ATMP classification is a key milestone for companies developing

Back to news